Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives

References

• American Cancer Society. About prostate cancer. 2016 [accessed 2018 Oct 11]. https://www.cancer.org/cancer/prostate-cancer.html.
   Google Scholar
• Prostate Cancer Foundation. Prostate cancer treatment. 2018 [accessed 2018 Oct 11]. https://www.pcf.org/about-prostate-cancer/prostate-cancer-treatment/.
   Google Scholar
• National Cancer Institute. Prostate cancer treatment. 2018 [accessed 2018 Oct 11]. https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq.
   Google Scholar
• Cancer.Net. Prostate cancer guide. 2018 [accessed 2018 Oct 11]. https://www.cancer.net/cancer-types/prostate-cancer/types-treatment.
   Google Scholar
• Institute, N.C. Immune checkpoint inhibitor. [accessed 2019 May]. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immune-checkpoint-inhibitor.
   Google Scholar
• Walker LS. Treg and CTLA-4: two intertwining pathways to immune tolerance. J Autoimmun. 2013;45:1–13. doi:10.1016/j.jaut.2013.06.006.
   PubMed Web of Science ®Google Scholar
• Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev. 2011;241(1):180–205. doi:10.1111/j.1600-065X.2011.01011.x.
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233–258. doi:10.1146/annurev.immunol.14.1.233.
   PubMed Web of Science ®Google Scholar
• Sansom DM. CD28, CTLA-4 and their ligands: who does what and to whom? Immunology. 2000;101(2):169–177. doi:10.1046/j.1365-2567.2000.00121.x.
   PubMed Web of Science ®Google Scholar
• Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity. 1996;4:535–543.
   PubMed Web of Science ®Google Scholar
• Tai X, Van Laethem F, Pobezinsky L, Guinter T, Sharrow SO, Adams A, Granger L, Kruhlak M, Lindsten T, Thompson CB, et al. Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells. Blood. 2012;119(22):5155–5163. doi:10.1182/blood-2011-11-388918.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008;13(Suppl 4):2–9. doi:10.1634/theoncologist.13-S4-2.
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–1736. doi:10.1126/science.271.5256.1734.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006;18(2):206–213. doi:10.1016/j.coi.2006.01.011.
   PubMed Web of Science ®Google Scholar
• Movva S, Verschraegen C. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management. Expert Opin Biol Ther. 2009;9(2):231–241. doi:10.1517/14712590802643347.
   PubMed Web of Science ®Google Scholar
• Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010;37(5):533–546. doi:10.1053/j.seminoncol.2010.09.015.
   PubMed Web of Science ®Google Scholar
• Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. 2013;34(11):556–563. doi:10.1016/j.it.2013.07.003.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704. doi:10.1146/annurev.immunol.26.021607.090331.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206(13):3015–3029. doi:10.1084/jem.20090847.
   PubMed Web of Science ®Google Scholar
• Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O’Shea MA, Fauci AS. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol. 2008;181(10):6738–6746. doi:10.4049/jimmunol.181.10.6738.
   PubMed Web of Science ®Google Scholar
• Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009;229(1):114–125. doi:10.1111/j.1600-065X.2009.00767.x.
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293–12297. doi:10.1073/pnas.192461099.
   PubMed Web of Science ®Google Scholar
• Isaacsson Velho P, Antonarakis ES. PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol. 2018;11(5):475–486. doi:10.1080/17512433.2018.1464388.
   PubMed Web of Science ®Google Scholar
• Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561. doi:10.3389/fphar.2017.00561.
   PubMed Web of Science ®Google Scholar
• Dotti G. Blocking PD-1 in cancer immunotherapy. Blood. 2009;114(8):1457–1458. doi:10.1182/blood-2009-05-223412.
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98–106. doi:10.1097/COC.0000000000000239.
   PubMed Web of Science ®Google Scholar
• Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86. doi:10.3389/fonc.2018.00086.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097.
   PubMed Web of Science ®Google Scholar
• Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van Den Eertwegh AJM, Krainer M, Houede N, Santos R, Mahammedi H, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–712. doi:10.1016/S1470-2045(14)70189-5.
   PubMed Web of Science ®Google Scholar
• Drake C, Kwon ED, Fizazi K, Bossi A, van Den Eertwegh AJ, Logothetis C, Scher HI, Beer TM, McHenry B, Liu D, et al. Results of subset analyses on overall survival (OS) from study CA184-043: ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2014 [accessed 2018 Oct 11];32:2. doi:10.1200/jco.2014.32.4_suppl.2.
   Google Scholar
• Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35(1):40–47. doi:10.1200/JCO.2016.69.1584.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Safety and efficacy study of ipilimumab 3 mg/kg versus ipilimumab 10 mg/kg in subjects with metastatic castration resistant prostate cancer who are chemotherapy naive. 2016 [accessed 2018 Oct 11]. https://clinicaltrials.gov/ct2/show/NCT02279862.
   Google Scholar
• Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, Giles F. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6(1):39. doi:10.1186/s40425-018-0349-3.
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;73(12):3591–3603. doi:10.1158/0008-5472.CAN-12-4100.
   PubMed Web of Science ®Google Scholar
• Ardiani A, Gameiro SR, Kwilas AR, Donahue RN, Hodge JW. Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget. 2014;5(19):9335–9348. doi:10.18632/oncotarget.2429.
   PubMed Web of Science ®Google Scholar
• Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res. 2008;14(11):3536–3544. doi:10.1158/1078-0432.CCR-07-4025.
   PubMed Web of Science ®Google Scholar
• Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang K-Y, Ferrone S, Gameiro SR. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer. 2013;133(3):624–636. doi:10.1002/ijc.28070.
   PubMed Web of Science ®Google Scholar
• CinicalTrials.gov. Comparison study of MDX-010 (CTLA-4) alone and combined with docetaxel in the treatment of patients with hormone refractory prostate cancer. [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT00050596?term=MDX010-07&rank=1.
   Google Scholar
• Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):501–508. doi:10.1016/S1470-2045(12)70006-2.
   PubMed Web of Science ®Google Scholar
• Coyne GO, Jochems C, Heery C, Singh H, Surolia I, Riley R, Madan R, Dahut W, Steinberg S, Gulley J, et al. Abstract 5012: A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. 2014 [accessed 2018 Oct 11]. http://cancerres.aacrjournals.org/content/74/19_Supplement/5012.
   Google Scholar
• Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Ejadi S, Wallmark JM, Keam B, Delord J-P, Aggarwal R, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol. 2018;29(8):1807–1813. doi:10.1093/annonc/mdy232.
   PubMed Web of Science ®Google Scholar
• De Bono J, Goh JC, Ojamaa K, Piulats Rodriguez JM, Drake CG, Hoimes CJ, Wu H, Poehlein CH, Antonarakis ES. KEYNOTE-199: pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2018 [accessed 2018 Oct 11];36:5007. doi:10.1200/JCO.2018.36.15_suppl.5007.
   Google Scholar
• CinicalTrials.gov. Trial of pembrolizumab in metastatic castration resistant prostate cancer (PERSEUS1). [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT03506997?term=PERSEUS1&rank=1.
   Google Scholar
• CinicalTrials.gov. Pembrolizumab in metastatic castration resistant prostate cancer (mCRPC) with or without DNA damage repair defects. [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT03248570?term=CC+16557&rank=1.
   Google Scholar
• Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN, Zoubeidi A. PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget. 2015;6(1):234–242. doi:10.18632/oncotarget.v6i1.
   PubMedGoogle Scholar
• Graff J, Alumkal JJ, Thompson RF, Moran A, Thomas GV, Wood MA, Drake CG, Slottke R, Beer TM. Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): extended follow up. J Clin Oncol. 2018[accessed 2018 Oct 11];36:5047. doi:10.1200/JCO.2018.36.15_suppl.5047.
   Google Scholar
• CinicalTrials.gov. Study of pembrolizumab (MK-3475) combination therapies in metastatic castration-resistant prostate cancer (MK-3475-365/KEYNOTE-365). [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT02861573?term=KEYNOTE-365&rank=1.
   Google Scholar
• CinicalTrials.gov. Vaccine therapy and pembrolizumab in treating patients with hormone-resistant, metastatic prostate cancer. [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT02499835?term=NCT02499835&rank=1.
   Google Scholar
• McNeel DG, Eickhoff JC, Wargowski E, Zahm C, Staab MJ, Straus J, Liu G. Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 2018;9(39):25586–25596. doi:10.18632/oncotarget.25387.
   PubMedGoogle Scholar
• Rekoske BT, Smith HA, Olson BM, Maricque BB, McNeel DG. PD-1 or PD-L1 blockade restores antitumor efficacy following SSX2 epitope-modified DNA vaccine immunization. Cancer Immunol Res. 2015;3(8):946–955. doi:10.1158/2326-6066.CIR-14-0206.
   PubMed Web of Science ®Google Scholar
• Zahm CD, Colluru VT, McNeel DG. Vaccination with high-affinity epitopes impairs antitumor efficacy by increasing PD-1 expression on CD8(+) T cells. Cancer Immunol Res. 2017;5(8):630–641. doi:10.1158/2326-6066.CIR-16-0374.
   PubMed Web of Science ®Google Scholar
• Rekoske BT, Olson BM, McNeel DG. Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. Oncoimmunology. 2016;5(6):e1165377. doi:10.1080/2162402X.2016.1165377.
   PubMed Web of Science ®Google Scholar
• CinicalTrials.gov. Combination study of guadecitabine and pembrolizumab. (HyPeR). [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT02998567?term=NCT02998567&rank=1
   Google Scholar
• National Cancer Institute. guadecitabine. 2018 [accessed 2018 Oct 11]. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/guadecitabine.
   Google Scholar
• CinicalTrials.gov. Study evaluating the addition of pembrolizumab to radium-223 in mCRPC. https://clinicaltrials.gov/ct2/show/NCT03093428?term=16-498&rank=1.
   Google Scholar
• National Cancer Institute. HER2Bi-armed activated T cells. 2018 [accessed 2018 Oct 11]. [accessed 2019 Jun 28]. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/her2bi-armed-activated-t-cells.
   Google Scholar
• Chapman RW, Minnicozzi M, Celly CS, Phillips JE, Kung TT, Hipkin RW, Fan X, Rindgen D, Deno G, Bond R, et al. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther. 2007;322(2):486–493. doi:10.1124/jpet.106.119040.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. androgen receptor antisense oligonucleotide AZD5312. 2018 [accessed 2018 Oct 11]. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/androgen-receptor-antisense-oligonucleotide-azd5312.
   Google Scholar
• CinicalTrials.gov. ARRx in combination with enzalutamide in metastatic castration resistant prostate cancer. [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT03300505?term=ARRO-CITO&rank=1.
   Google Scholar
• CinicalTrials.gov. Rucaparib and nivolumab in patients with prostate or endometrial cancer. [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT03572478?term=IRB18-0154&rank=1.
   Google Scholar
• CinicalTrials.gov. An investigational immunotherapy study of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in metastatic castration-resistant prostate cancer (CheckMate 9KD). [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT03338790?term=CheckMate+9KD&rank=1.
   Google Scholar
• CinicalTrials.gov. Phase I/II study of the anti-programmed death ligand-1 antibody MEDI4736 in combination with olaparib and/or cediranib for advanced solid tumors and advanced or recurrent ovarian, triple negative breast, lung, prostate and colorectal cancers. [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT02484404?term=NCT02484404&rank=1.
   Google Scholar
• CinicalTrials.gov. A Phase 1 clinical study of AZD4635 in patients with advanced solid malignancies. [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT02740985?term=REFMAL+435&rank=1.
   Google Scholar
• CinicalTrials.gov. Tremelimumab + durvalumab chemotherapy naive CRPC. [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT03204812?term=NCT03204812&rank=1.
   Google Scholar
• CinicalTrials.gov. Durvalumab with or without tremelimumab in metastatic castration resistant prostate cancer. [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT02788773?term=NCT02788773&rank=1.
   Google Scholar
• Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65(10):4389–4400. doi:10.1158/0008-5472.CAN-04-4409.
   PubMed Web of Science ®Google Scholar
• Ma S-R, Deng -W-W, Liu J-F, Mao L, Yu G-T, Bu -L-L, Kulkarni AB, Zhang W-F, Sun Z-J. Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma. Mol Cancer. 2017;16(1):99. doi:10.1186/s12943-017-0665-0.
   PubMedGoogle Scholar
• Leone RD, Lo YC, Powell JD. A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J. 2015;13:265–272. doi:10.1016/j.csbj.2015.03.008.
   PubMed Web of Science ®Google Scholar
• CinicalTrials.gov. A dose escalation and confirmation study of PT-112 in advanced solid tumors in combination with avelumab (PAVE-1). [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT03409458?term=PAVE-1&rank=1.
   Google Scholar
• Heery CR, O’Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marté JL, Lepone LM, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18(5):587–598. doi:10.1016/S1470-2045(17)30239-5.
   PubMed Web of Science ®Google Scholar
• CinicalTrials.gov. Javelin Parp Medley: Avelumab plus talazoparib in locally advanced or metastatic solid tumors. https://clinicaltrials.gov/ct2/show/NCT03330405?term=Parp+Medley&rank=1.
   Google Scholar
• CinicalTrials.gov. Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor. https://clinicaltrials.gov/ct2/show/NCT02814669?term=BO30013&rank=1.
   Google Scholar
• CinicalTrials.gov. Clinical study of atezolizumab (Anti-PD-L1) and Sipuleucel-T in patients who have asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT03024216?term=Rosser-2015-4&rank=1.
   Google Scholar
• CinicalTrials.gov. A study of atezolizumab (Anti-PD-L1 Antibody) in combination with enzalutamide in participants with metastatic castration-resistant prostrate cancer (mCRPC) after failure of an androgen synthesis inhibitor and failure of, ineligibility for, or refusal of a taxane regimen (IMbassador250). [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT03016312?term=IMbassador250&rank=1.
   Google Scholar
• National Cancer Institute. adenosine-A2A receptor antagonist CPI-444. 2018. [accessed 2019 Jun 28]. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/adenosine-a2a-receptor-antagonist-cpi-444.
   Google Scholar
• National Cancer Institute. cabozantinib-s-malate. 2018 [accessed 2018 Oct 11]. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cabozantinib-s-malate.
   Google Scholar
• Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol. 2016;34(25):3005–3013. doi:10.1200/JCO.2015.65.5597.
   PubMed Web of Science ®Google Scholar
• CinicalTrials.gov. Study of cabozantinib in combination with atezolizumab to subjects with locally advanced or metastatic solid tumors. [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT03170960?term=XL184-021&rank=1.
   Google Scholar
• Pakkala S, Owonikoko TK. Immune checkpoint inhibitors in small cell lung cancer. J Thorac Dis. 2018;10(Suppl 3):S460–S467. doi:10.21037/jtd.2017.12.51.
   PubMed Web of Science ®Google Scholar
• Lugowska I, Teterycz P, Rutkowski P. Immunotherapy of melanoma. Contemp Oncol (Pozn). 2018;22(1A):61–67. doi:10.5114/wo.2018.73889.
   PubMedGoogle Scholar
• Taieb J, Moehler M, Boku N, Ajani JA, Yañez Ruiz E, Ryu M-H, Guenther S, Chand V, Bang Y-J. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: current status and future perspectives. Cancer Treat Rev. 2018;66:104–113. doi:10.1016/j.ctrv.2018.04.004.
   PubMed Web of Science ®Google Scholar
• Tolkach Y, Kristiansen G. The heterogeneity of prostate cancer: a practical approach. Pathobiology. 2018;85(1–2):108–116. doi:10.1159/000477852.
   PubMed Web of Science ®Google Scholar
• Yadav SS, Stockert JA, Hackert V, Yadav KK, Tewari AK. Intratumor heterogeneity in prostate cancer. Urol Oncol. 2018;36(8):349–360. doi:10.1016/j.urolonc.2018.05.008.
   PubMed Web of Science ®Google Scholar
• Shoag J, Barbieri CE. Clinical variability and molecular heterogeneity in prostate cancer. Asian J Androl. 2016;18(4):543–548. doi:10.4103/1008-682X.178852.
   PubMed Web of Science ®Google Scholar
• Boyd LK, Mao X, Lu YJ. The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol. 2012;9(11):652–664. doi:10.1038/nrurol.2012.185.
   PubMed Web of Science ®Google Scholar
• Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of immune system aging. J Clin Invest. 2013;123(3):958–965. doi:10.1172/JCI64096.
   PubMed Web of Science ®Google Scholar
• Society AC Prostate cancer risk factors. 2016 [accessed 2019 21 January]. https://www.cancer.org/cancer/prostate-cancer/causes-risks-prevention/risk-factors.html.
   Google Scholar
• Proctor RN. Tobacco and the global lung cancer epidemic. Nat Rev Cancer. 2001;1(1):82–86. doi:10.1038/35094091.
   PubMed Web of Science ®Google Scholar
• Narayanan DL, Saladi RN, Fox JL. Ultraviolet radiation and skin cancer. Int J Dermatol. 2010;49(9):978–986. doi:10.1111/j.1365-4632.2010.04474.x.
   PubMed Web of Science ®Google Scholar
• Kanavy HE, Gerstenblith MR. Ultraviolet radiation and melanoma. Semin Cutan Med Surg. 2011;30(4):222–228. doi:10.1016/j.sder.2011.08.003.
   PubMed Web of Science ®Google Scholar
• Correa P, Piazuelo MB. Helicobacter pylori infection and gastric adenocarcinoma. US Gastroenterol Hepatol Rev. 2011;7:59–64.
   PubMedGoogle Scholar
• National Cancer Institute. microsatellite instability. 2018 [accessed 2018 Oct 11]. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/microsatellite-instability.
   Google Scholar
• Hempelmann JA, Lockwood CM, Konnick EQ, Schweizer MT, Antonarakis ES, Lotan TL, Montgomery B, Nelson PS, Klemfuss N, Salipante SJ, et al. Microsatellite instability in prostate cancer by PCR or next-generation sequencing. J Immunother Cancer. 2018;6(1):29. doi:10.1186/s40425-018-0341-y.
   PubMed Web of Science ®Google Scholar
• Schweizer MT, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Nelson PS, Yu EY, Montgomery B, et al. Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Oncotarget. 2016;7(50):82504–82510. doi:10.18632/oncotarget.12697.
   PubMedGoogle Scholar
• Palmieri G, Colombino M, Cossu A, Marchetti A, Botti G, Ascierto PA. Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy? J Transl Med. 2017;15(1):17. doi:10.1186/s12967-017-1119-6.
   PubMedGoogle Scholar
• Ji JH, Song H-N, Kim RB, Oh SY, Lim HY, Park JO, Park SH, Kim MJ, Lee SI, Ryou SH, et al. Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC). Jpn J Clin Oncol. 2015;45(3):256–260. doi:10.1093/jjco/hyu210.
   PubMed Web of Science ®Google Scholar